DMT-assisted therapy: changing the way we think about depressive disorders

Our CMSO Carol Routledge spoke to Bioscience Today about the world-leading psychedelic therapy research happening in the UK, the importance of therapy in our clinical trails and why DMT could be the most clinically practical of the psychedelics.

During the discussion, Dr Routledge called attention to the unique position of the UK in the world of psychedelic-assisted therapy:

What is exciting is that the UK is quickly forging a leadership position in the world of psychedelic-assisted therapy research. This is thanks to the world-leading academic institutions – such as Imperial College London – that are supporting various clinical trials. The government should be delighted that such trailblazing innovation is happening right on its shores and grab the opportunity to lead on the global stage with both hands.”


About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: